USPTO serial 79343374
CENYX BIOTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 26, 2024
- Examiner
- SIMCOX, KYLE DUNCAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CENYX BIOTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 Pennsylvania Avenue NW, Suite 9000Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compounds, wrapping wafers, edible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicines, namely, medicinal preparations in the nature of pills, tablets, capsules, caplets, liquid drops, sachets, oral liquids, suspensions, liquids, semi-solids, creams, syrups, ointments, lotions, gels, sprays, emulations, oils, pessaries, suppositories, granules and films for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes | ACTIVE | — |
| 042 | Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysis, and evaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cenyx Biotech Inc.
- Other trademarks owned by Cenyx Biotech Inc.
- Other trademarks owned by Cenyx Biotech Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named CENYX BIOTECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 17, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 6, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 6, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 27, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 26, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 20, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 20, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 18, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 29, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 29, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 29, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 29, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 29, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 7, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 24, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 24, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 24, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 30, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 11, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 10, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 28, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 24, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 23, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |